INTRODUCTION
Hepatitis C virus (HCV) is one of major causes of chronic liver disease worldwide. HCV is hepatotrophic, but not directly cytopathic and elicit progressive liver injuries resulting in end-stage liver disease unless effectively eradicated (1) . Epidemiological studies have revealed that more than 80% of acutely HCV-infected patients fail to eradicate the virus and they subsequently develop chronic hepatitis (1) . It has been proposed that the ability of infected hosts to mount vigorous and sustained cellular immune reactions to HCV is necessary for control in primary infection (2) . Once HCV survives the initial interaction with the host immune system, it uses several means to nullify the selective immunological pressure during the later phases of infection. First, the virus alters its antigenic epitopes recognized by T cells and neutralizing antibodies to escape immune surveillance. Second, HCV also subverts immune functions in an antigen-specific manner, from innate to adaptive immunity (3) .
Cumulative reports have shown that innate immune system dictates the direction and magnitude of subsequent adaptive immune response. It is generally accepted that HCV-specific CD8 + T cells are responsible for HCV elimination by inducing hepatocyte apoptosis (2 + T cells to the infected liver may result in weak liver inflammation that is not sufficient for HCV eradication (5) .
In this paper, we discuss the current understandings of the roles of innate immunity in the pathogenesis of HCV infection as well as efficacy of anti-HCV therapy, especially focused on interferons (IFN), DCs, NK cells and NKT cells.
KEY PLAYERS IN IMMUNE RESPONSES TO VIRAL HEPATITIS
After HCV infects the liver, viral replication continues and viral particles are continuously released into the circulation. The first lines of defense are provided by NK and NKT cells, of which populations are relatively increased in the liver compared to the periphery. These cells are activated in the liver, where expression of IFN-alfa and IFN-inducible genes are extremely high during the early phase of hepatitis virus infection (6) . Activated NK and NKT cells secrete IFN-gamma, which inhibits replication of HCV through a non-cytolytic mechanism (Figure 1-a) (7) .
Dendritic cells (DCs) or resident macrophages in the liver are capable of taking up viral antigens, and processing and presenting them to other immune cells (Figure 1-b) (4) . Since DCs express distinct sets of toll-like receptors (TLRs) (8) , it is likely that some viral components stimulate DCs through cytosolic ligation of TLRs. DCs develop a mature phenotype and migrate to lymphoid tissues (Figure 1-c) , where they stimulate effectors, including T cells and B cells (Figure 1-d) . Following the encounter of DCs with other cells, DCs secrete various cytokines (IL-12, TNF-alfa, IFN-alfa and IL-10) instructing or regulating the functions of the adjacent cells (4) . In addition to these cytokines, DCs express various co-stimulatory molecules and ligands to enhance or limit the functions of immune and infected cells. The existence of functionally and ontogenetically distinct DC subsets has been reported; i.e., myeloid DC (MDC) and plasmacytoid DC (PDC) (9) . MDC predominantly produce IL-12 or TNF-alfa following proinflammatory stimuli, while PDC release a considerable amount of IFN-alfa upon virus infection depending on the immune stimulus; both cytokines in actuality can be made by both cells. Helper T cells have an immunoregulatory function mediated by the secretion of cytokines that support either cytotoxic T lymphocyte (CTLs) generation (Th1 with secretion of IL-2, IFN-gamma and TNF-alfa) or B cell function and antibody production (Th2 with secretion of IL-4, IL-5, IL-10 and IL-13) (Figure 1-e) . DC ontogeny and DC-derived cytokines are crucially associated with the polarization of helper T cell subsets.
It is generally accepted that adaptive immunity performs a critical role during the clinical courses of hepatitis. The involvement of antigen-specific CD4 + T cells in HCV eradication has been well described during both acute or chronic infection (10 (Figure 1-f ) and constitute the critical element in the eradication of virus-infected cells (Figure 1-g ).
INNATE IMMUNITY IN HCV INFECTION

Toll-like receptors and retinoic acid inducible gene-I as sensors for virus infection
Gene expression analyses in HCV-infected liver revealed that HCV triggers expression of type I IFN and IFN-induced genes during primary infection regardless of the outcomes (6) . However, the HCV viral load does not decrease in the early phase, suggesting that HCV impedes the execution of anti-viral machineries. Several HCVderived proteins are involved in the suppression on the signaling pathways inducing anti-viral proteins, such as interferon regulatory factor (IRF)-3 (11), NF-kappa B and RNA-dependent protein kinases (PKR) (12) . Mammalian toll-like receptors (TLRs) sense some pathogen-associated molecular patterns embedded in virus components and then induce inflammatory cytokines or type-I IFNs, resulting in the augmentation of anti-virus immune reactions (8) . Retinoic acid inducible gene-I (RIG-I) is a cytosolic molecule that senses dsRNA of virus replicative intermediate, which subsequently activates IRF-3 and NF-kappa B pathways (13) . By using HCV subgenomic replicon system, it has been demonstrated that HCV NS3/4A proteins influences on the functions of adaptor molecules mediating TLR-dependent and RIG-Idependent pathways, resulting in an impairment of the induction of IFN-beta as well as subsequent interferonstimulated genes (14, 15) . However, it is yet to be proven whether the results obtained from HCV replicon are applicable or not for HCV-infected individuals.
Large-scale cohort study on US veterans revealed that the prevalence of various infectious diseases, including virus, bacteria and parasites, in HCV-infected individuals is significantly higher than those in uninfected controls (16) . These observations suggest that first-line defense against pathogens, of which system is initiated by TLR/RIG-I stimulation, is functionally impaired in HCV infection. To investigate the roles of TLR/RIG-I in HCV infection, we compared their expressions and the functions in MDC and PDC between the patients and donors. In MDC from HCVinfected patients, TLR2, TLR4 and RIG-I expression were significantly higher than those in healthy counterparts. Of particular interest, regardless of the higher expressions, specific agonists for these sensors stimulated patients MDC to induce lesser amount of IFN-beta and TNF-alfa compared to donor MDC (unpublished data). These results show that the signal transduction via these receptors is strongly impeded in HCV infection. Inconsistent with the findings of MDC, we previously reported that TLR2 expression on monocytederived DCs (MoDCs) in chronic hepatitis C is lower than those in healthy donors (17) . Since MoDC is an in vitrogenerated DC mimic, the opposite results of TLR2 in HCV infection might be explained by impaired ability of MoDC to mature in response to cytokines, as reported elsewhere (18) . Further investigation is needed to clarify which TLR or RIG-I is predominantly utilized by HCV to evoke immune reactions.
Blood DC subsets
Impaired antigen presentation by DC might be involved in the failure of the maintenance of sustained HCV-specific T cell response. Monocyte-derived DCs (MoDCs) generated from hepatitis C patients have an impaired ability to stimulate allogeneic CD4 + T cells (19, 20) . Functional impairment of DC diminished when HCV had been eradicated from patients, revealing the evidence of HCV-induced DC disability (19) . In addition to in vitrogenerated DCs, the alterations in number and function of circulating blood DC have been reported in HCV infection (21, 22) .
Direct HCV infection of DCs might be one of the plausible mechanisms of DC dysfunction in chronic hepatitis C. The HCV genome has been reported to be isolated from MoDCs or blood DCs (19) . However, these results need to be interpreted carefully, since contamination with free virus in blood cannot be ruled out when amplifying PCR techniques are used. To exclude this possibility, HCV pseudovirus has been developed to investigate the cell tropisms of HCV as well as to determine putative HCV entry receptors to cells. By using this, MDC, but not PDC, displayed susceptibility to HCV pseudovirus possessing chimeric HCV E1/E2 proteins (23).
Several criticisms have been raised recently about DC dysfunction in the setting of chronic HCV infection (24) , failing to demonstrate any DC defects which may have to do with differences in the populations studied. Cohort studies on chimpanzees following HCV infection showed that functional impairment of DCs was observed in some cases but was not a prerequisite of persistent infection (25) . Further study needs to be done to clarify whether DCs are indeed disabled in the setting of human chronic hepatitis C and furthermore whether this contributes to the development of HCV persistence or it is simply a consequence of active HCV infection.
Natural killer cells
Natural killer cells express various functional receptors; the one group that transduces inhibitory signals (Killer Inhibitory Receptors/KIRs, CD94, NKG2A) and the other does activating signals (NKG2D). The function of NK cells is dynamically regulated in vivo by the balance between expressions of counteracting receptors and their association with relevant ligands (26) . First, we compared the expressions of NK cell receptor between HCV-infected patients and healthy donors. As for inhibitory receptors, KIR expressions are not different between the groups; however, CD94 and NKG2A expressions are higher in patients than controls (27) . In contrast, activating receptor NKG2D expression is comparable between the groups (Figure 2) . It is yet to be determined how the expression of NK cell receptor is regulated. In our hands, HCV pseudovirus did not enter purified NK cells, suggesting that NK cells are not susceptible to direct HCV infection (unpublished data). Thus, some soluble factors and/or direct binding of HCV particles to NK cells might be the cause of NK receptor dysregulation. (28) . Interestingly, DCs from HCV-infected patients are unresponsive to exogenous IFN-alfa to enhance MICA/B expression and fail to activate NK cells (28) . It is tempting to speculate that the impairment of DCs in NK cell activation is responsible for the failure of HCV control in the early phase of primary HCV infection, where HCV continues to replicate in spite of high-level IFN-alfa expression in the liver. Alternatively, NK cells from HCV-infected patients down-regulate DC functions in the presence of hepatocytes by secreting suppressive cytokines, IL-10 and TGF-beta1 (27) . Such functional alteration of NK cells in HCV infection was ascribed to the enhanced expression of inhibitory receptor NKG2A/CD94 compared to the healthy counterparts (27) . Further study is necessary to determine if the NK-mediated DC suppression is instrumental or not in acute HCV infection.
Natural killer T cells
Natural killer T (NKT) cells are a unique lymphocyte subset co-expressing T-cell receptor (TCR) and NK cell markers (29) . The NKT cell population is highly heterogeneous according to the differences in types and tissue distribution; invariant (or classical) NKT (iNKT) cells express an invariant TCR, composed of Valfa24-JalfaQ preferentially paired with Vbeta11 in humans (29) , whereas non-invariant NKT cells express diverse TCR. Invariant NKT cells recognize glycolipid antigens presented on CD1d expressed by DCs (29) . Although endogenous ligands of iNKT cells are little known, alfagalactosyl-ceramide (alfaGalCer) has been used as a surrogate for natural ligands. In contrast, non-invariant NKT cells are activated by CD1d-dependent manner but are not reactive to alfaGalCer. Baron et al. reported that, in hepatitis B virus-transgenic mice, non-invariant NKT cells are critically involved in acute liver injury (30) . As for a human counterpart, Exley et al. observed that CD1d restricted non-invariant NKT cells infiltrate in HCVinfected liver, where they presumably exert their promoting role in liver inflammation (31 (35, 36) , however, their functional roles in HCV-infected patients are largely unknown. We thus compared the frequency and the cytokine producing capacity of iNKT cells in peripheral blood between chronic hepatitis C patients and healthy individuals. Furthermore, to analyze the functions of activated iNKT cells, we expanded iNKT cells by the stimulation with alfaGalCer-loaded DCs. We demonstrate that the number and functions of iNKT cells from HCV-infected patients are comparable with those from healthy subjects at the steady state ( Figure 3A ) (37) . By contrast, activated iNKT cells from patients released more Th2 cytokines, most significantly IL-13, than those from the controls ( Figure 3B ) (37) . Recently, other groups have reported that IL-4 and IL-13 from fresh iNKT cells were increased in liver cirrhosis caused by HBV or HCV, implying that these cells are pro-fibrogenic to the liver (38) . If this is the case, our findings suggest that iNKT cells in chronic HCV infection are pro-fibrogenic per se even in the pre-cirrhotic stage. The reason why iNKT cells in HCV infection are Th2-biased needs to be further investigated.
ADAPTIVE IMMUNITY IN HCV INFECTION
Many reports have been published on the importance of CD4 + T cell response in the clearance and control of HCV. In chronic hepatitis C patients, HCVspecific CD4 + T cells were functionally impaired and their activity was not sustained (39) , which was in clear contrast with resolved cases. Inoculation studies of infectious HCV to recovered chimpanzees demonstrated that CD4 + T cell help was indispensable for the development of effective CD8 + T cell response to protect from HCV persistence (40) .
With regard to HCV-specific CD8 + T cells observed during the chronic stages of disease, conflicting results have been reported for their roles in HCV replication and liver inflammation. Several investigators have shown that the HCV-specific CTL response is inversely correlated with viral load, suggesting its inhibitory capacity on HCV replication (41) . However, others did not find a significant relationship between these parameters (42) . HCV-specific CD8 + T cells in chronic hepatitis C patients possess lesser capacity to proliferate and produce less IFN-gamma in response to HCV antigens. Since CD8 + T cells are reported to be involved in HCVinduced liver inflammation, inefficient CD8 + T cells may evoke only milder hepatocyte injury, which level is not sufficient for HCV eradication (5).
Several plausible mechanisms have been proposed for T cell functional failure observed in chronic HCV infection (3): 1) HCV escape mutation, 2) primary T Figure 4 . Improvement of Th1-inducing ability of dendritic cells by IFN-alfa and ribavirin from chronic hepatitis C patients with sustained virological response in combination therapy. Monocyte-derived dendritic cells (DC) were generated with GM-CSF and IL-4 in the presence or absence of IFN-alfa and ribavirin and were cultured with allogeneic naïve CD4 + T cells for 6 days. On day 4 of the culture, half of the supernatants were collected for the assessment of IL-2. After 6 days, the cultured cells were stimulated with phorbol myrisate acetate and ionomycin for 24 hours. The results of IFN-gamma (A) and IL-2 (B) determined by ELISA were compared among them in the SVR and non-SVR group. The results are expressed as mean + SE from five SVR and nine non-SVR patients. SVR, sustained virological responder in 24 weeks of IFN-α and ribavirin therapy. *P < 0.05 by Mann-Whitney U-test.
cell failure or T cell exhaustion, 3) impaired antigen presentation, 4) suppression by HCV proteins, 5) impaired T cell maturation, 6) suppression by regulatory T cells and 7) tolerogenic environment in the liver.
IMMUNE RESPONSE DURING ANTI-VIRAL THERAPY
Anti-viral agents, pegylated (PEG) IFN-alfa and ribavirin, have been widely used for the treatment of chronic HCV infection in order to prevent the development to liver cirrhosis and hepatocellular caricinoma (1) . In addition to providing direct inhibition of viral replication, these agents modulate antiviral immune responses, which greatly contribute to the successful therapeutic response. Earlier studies reported that HCV-specific CD8 + T cell response, as examined by CTL precursor frequency, was not enhanced after IFN-alfa monotherapy (43) . Furthermore, analyses of MHC class-I tetramer-positive cells in patients who underwent IFN-alfa and ribavirin therapy revealed that CD8 + T cells did not increase following treatment and they were not associated with outcome (44). Combination therapy of IFN-alfa and ribavirin increases antigen-specific CD4 + T cell proliferation and IFN-gamma production by CD4 + T cells (45, 46) . The "vigor" of the CD4 + T cell response to HCV eradication is reported to be variable, something which is considered quite controversial (44).
Currently, no data is available for the involvement of innate immunity in the efficacy of IFN-alfabased anti-HCV therapy. We thus examined whether IFNalfa and ribavirin give a positive impact on DC capacity to induce CD4 + T cell (Th1) response. By using in vitro culture system, monocyte-derived DC from chronic hepatitis C patients were impaired in the ability to drive Th1 in response to IFN-alfa. When we compared such DC capacity between patients who cleared HCV (sustained virological responders, SVR) by IFN-alfa/ribavirin therapy and those who failed to do so, impaired DC function was restored in response to IFN-alfa/ribavirin in SVR patients but not in non-SVR ones ( Figure 4) (47) . These results imply that DC responsiveness to anti-viral agents is restored in patients who potentially gain favorable outcomes in IFN-alfa/ribavirin therapy.
Next, we aimed to elucidate if the frequency or function of DC and innate lymphocytes is related to the outcome of pegylated IFN-alfa and ribavirin therapy. In comparison with SVR patients, non-SVR ones and transient responders (TR) showed a decline of PDC frequency from weeks 1-12 and impaired DC function at the end of treatment ( Figure 5A ) (48) . The frequency of NK cells, as defined as CD3 -
CD56
+ cells, in SVR patients was lower than those in TR ones ( Figure 5B ). In contrast, the frequency of invariant NKT cells (Valfa24   +   Vbeta11 + cells) did not differ between the groups in the course of the treatment (data not shown). These results show that restoration of DC function is critically involved in favorable response in pegylated IFN-alfa/ribavirin therapy. In other words, DC system could be a target of therapeutic immune modulation.
The questions remain unsolved are if impaired immune system in chronic HCV infection is restored or not by the successful HCV eradication after anti-viral therapy. Controversial results have been reported about the durability of treatment-induced recovery in HCV-specific immune response (49, 50) , which seems to be clearly distinct from that observed in spontaneous HCV resolvers.
PERSPECTIVE
Protease inhibitors against HCV NS3/4A are now ready to use in clinics (51) . Since they possess potent ability to suppress HCV replication, they are quite promising as an alternative approach for non-responders in PEG-IFNalfa/ribavirin therapy. In addition to that, it is anticipated that protease inhibitors are able to restore innate -and CD123 high cells and NK cells were as CD3-negative and CD56 + cells, respectively. The results are expressed as mean + SE. *P < 0.05 by ANOVA. At the end of treatment (Week 48) and at Week 4 after the completion of therapy, monocyte-derived DC were generated from the patients or healthy donors and their allostimulatory capacity was evaluated by mixed lymphocyte reaction (MLR). The MLR ratio between patients and controls was determined from the counts per minute of 3 H-thymidine incorporated into CD4 + T cells at T cell/DC ratio of 10/1. The results are expressed as the mean + SE of 11 SVR and 11 transient responders. SVR and TR, sustained virological responders and transient responders in 48 weeks of pegylated IFN-alfa and ribavirin therapy.*P < 0.05 by Mann-Whitney U test.
immunity by disarming NS3/4A-mediated suppression on TLR/RIG-I-dependent or -independent pathways. Therefore, extensive immunological studies on the patients treated with protease inhibitors are needed to elucidate if the therapeutic modulation of innate immunity could shape HCV-specific adaptive immunity or not. The next steps in evolving innovative approaches to establish HCV-specific immunotherapy are to determine the means to, direct the magnitude, breadth, quality and duration of antigen-specific immune responses in a desired way. Active modulation of innate immunity may be one of the strategies to gain access to the goal.
